# MRK catalysts: Merck & Co., Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mrk/catalysts

> Merck & Co., Inc. (MRK) has 178 upcoming catalysts. The next is the KEYTRUDA® (pembrolizumab) primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, half-year only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Merck & Co., Inc. |
| Ticker | MRK (NYSE) |
| SEC CIK | 310158 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mrk |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 28, 2013 | [Belsomra (suvorexant) complete response letter (CRL)](https://sec-api.dev/pdufa/suvorexant) | MRK |  | completed, complete response letter | "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." ([FDA complete response letter database](https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA204569_20130628.pdf%22)) |
| January 28, 2016 | [Zepatier (elbasvir; grazoprevir) FDA approval](https://sec-api.dev/pdufa/elbasvir-grazoprevir) | MRK |  | completed, approved | "NDA208261 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20160128, review_priority PRIORITY; sponsor_name MSD SUB MERCK; product ZEPATIER (ELBASVIR; GRAZOPREVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208261%22)) |
| October 21, 2016 | [Zinplava (bezlotoxumab) FDA approval](https://sec-api.dev/pdufa/bezlotoxumab) | MRK |  | completed, approved | "BLA761046 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20161021, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product ZINPLAVA (BEZLOTOXUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761046%22)) |
| November 8, 2017 | [Prevymis (letermovir) FDA approval](https://sec-api.dev/pdufa/letermovir) | MRK |  | completed, approved | "NDA209940 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20171108, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product PREVYMIS (LETERMOVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209940%22)) |
| December 19, 2017 | [Steglatro (ertugliflozin) FDA approval](https://sec-api.dev/pdufa/ertugliflozin) | MRK |  | completed, approved | "NDA209803 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171219, review_priority STANDARD; sponsor_name MSD SUB MERCK; product STEGLATRO (ERTUGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209803%22)) |
| December 19, 2017 | [Segluromet (ertugliflozin; metformin hydrochloride) FDA approval](https://sec-api.dev/pdufa/ertugliflozin-metformin) | MRK |  | completed, approved | "NDA209806 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20171219, review_priority STANDARD; sponsor_name MSD SUB MERCK; product SEGLUROMET (ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209806%22)) |
| December 19, 2017 | [Steglujan (ertugliflozin; sitagliptin phosphate) FDA approval](https://sec-api.dev/pdufa/ertugliflozin-sitagliptin) | MRK |  | completed, approved | "NDA209805 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20171219, review_priority STANDARD; sponsor_name MSD SUB MERCK; product STEGLUJAN (ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209805%22)) |
| August 30, 2018 | [Pifeltro (doravirine) FDA approval](https://sec-api.dev/pdufa/doravirine) | MRK |  | completed, approved | "NDA210806 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20180830, review_priority STANDARD; sponsor_name MSD MERCK CO; product PIFELTRO (DORAVIRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210806%22)) |
| August 30, 2018 | [Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate) FDA approval](https://sec-api.dev/pdufa/doravirine-lamivudine-tenofovir-disoproxil) | MRK |  | completed, approved | "NDA210807 ORIG-1 (Type 4 - New Combination): submission_status AP, submission_status_date 20180830, review_priority STANDARD; sponsor_name MSD MERCK CO; product DELSTRIGO (DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210807%22)) |
| July 16, 2019 | [Recarbrio (cilastatin sodium; imipenem; relebactam) FDA approval](https://sec-api.dev/pdufa/cilastatin-imipenem-relebactam) | MRK |  | completed, approved | "NDA212819 ORIG-1 (Type 1 - New Molecular Entity and Type 4 - New Combination): submission_status AP, submission_status_date 20190716, review_priority PRIORITY; sponsor_name MSD MERCK CO; product RECARBRIO (CILASTATIN SODIUM; IMIPENEM; RELEBACTAM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212819%22)) |
| January 8, 2020 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-66 (Efficacy): submission_status AP, submission_status_date 20200108, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| January 29, 2020 | [Belsomra (suvorexant) label expansion decision](https://sec-api.dev/pdufa/suvorexant) | MRK |  | completed, approved | "NDA204569 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20200129, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product BELSOMRA (SUVOREXANT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA204569%22)) |
| April 28, 2020 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-80 (Efficacy): submission_status AP, submission_status_date 20200428, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 4, 2020 | [Recarbrio (cilastatin sodium; imipenem; relebactam) label expansion decision](https://sec-api.dev/pdufa/cilastatin-imipenem-relebactam) | MRK |  | completed, approved | "NDA212819 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20200604, review_priority PRIORITY; sponsor_name MSD MERCK CO; product RECARBRIO (CILASTATIN SODIUM; IMIPENEM; RELEBACTAM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212819%22)) |
| June 9, 2020 | [Bridion (sugammadex sodium) label expansion decision](https://sec-api.dev/pdufa/sugammadex) | MRK |  | completed, approved | "NDA022225 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20200609, review_priority STANDARD; sponsor_name MSD SUB MERCK; product BRIDION (SUGAMMADEX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022225%22)) |
| June 16, 2020 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-71 (Efficacy): submission_status AP, submission_status_date 20200616, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 29, 2020 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-84 (Efficacy): submission_status AP, submission_status_date 20200629, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| July 14, 2020 | [Isentress (raltegravir potassium) label expansion decision](https://sec-api.dev/pdufa/raltegravir) | MRK |  | completed, approved | "NDA203045 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20200714, review_priority STANDARD; sponsor_name MSD SUB MERCK; product ISENTRESS (RALTEGRAVIR POTASSIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA203045%22)) |
| October 2, 2020 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-70 (Efficacy): submission_status AP, submission_status_date 20201002, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| October 14, 2020 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-85 (Efficacy): submission_status AP, submission_status_date 20201014, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| November 13, 2020 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-88 (Efficacy): submission_status AP, submission_status_date 20201113, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| December 4, 2020 | [Janumet (metformin hydrochloride; sitagliptin phosphate) label expansion decision](https://sec-api.dev/pdufa/metformin-sitagliptin) | MRK |  | completed, approved | "NDA022044 SUPPL-48 (Efficacy): submission_status AP, submission_status_date 20201204, review_priority PRIORITY; sponsor_name MSD SUB MERCK; product JANUMET (METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022044%22)) |
| December 4, 2020 | [Januvia (sitagliptin) label expansion decision](https://sec-api.dev/pdufa/sitagliptin) | MRK |  | completed, approved | "NDA021995 SUPPL-47 (Efficacy): submission_status AP, submission_status_date 20201204, review_priority PRIORITY; sponsor_name MSD; product JANUVIA (SITAGLIPTIN PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA021995%22)) |
| January 19, 2021 | [Verquvo (vericiguat) FDA approval](https://sec-api.dev/pdufa/vericiguat) | MRK |  | completed, approved | "NDA214377 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210119, review_priority PRIORITY; sponsor_name MSD; product VERQUVO (VERICIGUAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214377%22)) |
| January 22, 2021 | [Bridion (sugammadex sodium) label expansion decision](https://sec-api.dev/pdufa/sugammadex) | MRK |  | completed, approved | "NDA022225 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20210122, review_priority STANDARD; sponsor_name MSD SUB MERCK; product BRIDION (SUGAMMADEX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022225%22)) |
| March 16, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-93 (Efficacy): submission_status AP, submission_status_date 20210316, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| May 5, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-97 (Efficacy): submission_status AP, submission_status_date 20210505, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| May 31, 2021 | [Noxafil (posaconazole) FDA approval](https://sec-api.dev/pdufa/posaconazole) | MRK |  | completed, approved | "NDA214770 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20210531, review_priority STANDARD; sponsor_name MSD MERCK CO; product NOXAFIL POWDERMIX KIT (POSACONAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214770%22)) |
| May 31, 2021 | [Noxafil (posaconazole) label expansion decision](https://sec-api.dev/pdufa/posaconazole) | MRK |  | completed, approved | "NDA205596 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20210531, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product NOXAFIL (POSACONAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205596%22)) |
| June 17, 2021 | [Noxafil (posaconazole) label expansion decision](https://sec-api.dev/pdufa/posaconazole) | MRK |  | completed, approved | "NDA205596 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20210617, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product NOXAFIL (POSACONAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205596%22)) |
| June 25, 2021 | [Bridion (sugammadex sodium) label expansion decision](https://sec-api.dev/pdufa/sugammadex) | MRK |  | completed, approved | "NDA022225 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210625, review_priority STANDARD; sponsor_name MSD SUB MERCK; product BRIDION (SUGAMMADEX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022225%22)) |
| July 1, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-100 (Efficacy): submission_status AP, submission_status_date 20210701, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| July 21, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-105 (Efficacy): submission_status AP, submission_status_date 20210721, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| August 10, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-102 (Efficacy): submission_status AP, submission_status_date 20210810, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| August 13, 2021 | [WELIREG® (belzutifan) FDA approval](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20210813, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| August 31, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-118 (Efficacy): submission_status AP, submission_status_date 20210831, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| September 17, 2021 | [Steglatro (ertugliflozin) label expansion decision](https://sec-api.dev/pdufa/ertugliflozin) | MRK |  | completed, approved | "NDA209803 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20210917, review_priority STANDARD; sponsor_name MSD SUB MERCK; product STEGLATRO (ERTUGLIFLOZIN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209803%22)) |
| September 17, 2021 | [Segluromet (ertugliflozin; metformin hydrochloride) label expansion decision](https://sec-api.dev/pdufa/ertugliflozin-metformin) | MRK |  | completed, approved | "NDA209806 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20210917, review_priority STANDARD; sponsor_name MSD SUB MERCK; product SEGLUROMET (ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209806%22)) |
| September 17, 2021 | [Steglujan (ertugliflozin; sitagliptin phosphate) label expansion decision](https://sec-api.dev/pdufa/ertugliflozin-sitagliptin) | MRK |  | completed, approved | "NDA209805 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20210917, review_priority STANDARD; sponsor_name MSD SUB MERCK; product STEGLUJAN (ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209805%22)) |
| October 13, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-122 (Efficacy): submission_status AP, submission_status_date 20211013, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| November 17, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-113 (Efficacy): submission_status AP, submission_status_date 20211117, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| December 3, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-112 (Efficacy): submission_status AP, submission_status_date 20211203, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| December 9, 2021 | [Zepatier (elbasvir; grazoprevir) label expansion decision](https://sec-api.dev/pdufa/elbasvir-grazoprevir) | MRK |  | completed, approved | "NDA208261 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20211209, review_priority STANDARD; sponsor_name MSD SUB MERCK; product ZEPATIER (ELBASVIR; GRAZOPREVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208261%22)) |
| December 17, 2021 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-120 (Efficacy): submission_status AP, submission_status_date 20211217, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| January 27, 2022 | [Pifeltro (doravirine) label expansion decision](https://sec-api.dev/pdufa/doravirine) | MRK |  | completed, approved | "NDA210806 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20220127, review_priority PRIORITY; sponsor_name MSD MERCK CO; product PIFELTRO (DORAVIRINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210806%22)) |
| January 27, 2022 | [Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate) label expansion decision](https://sec-api.dev/pdufa/doravirine-lamivudine-tenofovir-disoproxil) | MRK |  | completed, approved | "NDA210807 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20220127, review_priority PRIORITY; sponsor_name MSD MERCK CO; product DELSTRIGO (DORAVIRINE; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210807%22)) |
| February 4, 2022 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-95 (Efficacy): submission_status AP, submission_status_date 20220204, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| March 21, 2022 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-110 (Efficacy): submission_status AP, submission_status_date 20220321, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| May 2, 2022 | [Fosaprepitant Dimeglumine (fosaprepitant dimeglumine) label expansion decision](https://sec-api.dev/pdufa/fosaprepitant-dimeglumine) | MRK |  | completed, approved | "NDA022023 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20220502, review_priority STANDARD; sponsor_name MERCK AND CO INC; product EMEND (FOSAPREPITANT DIMEGLUMINE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022023%22)) |
| May 20, 2022 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-123 (Efficacy): submission_status AP, submission_status_date 20220520, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| December 16, 2022 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-127 (Efficacy): submission_status AP, submission_status_date 20221216, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| Jan 2023 | [Januvia (sitagliptin) FDA approval](https://sec-api.dev/pdufa/sitagliptin) | MRK |  | completed, approved | "While the key U.S. patent for Januvia, Janumet and Janumet XR claiming the sitagliptin compound expired in January 2023, as a result of favorable court rulings and settlement agreements related to a later expiring patent directed to the specific sitagliptin salt form of the products, the Company expects that Januvia and Janumet will not lose market exclusivity in the U.S. until May 2026 and Janumet XR will not lose market exclusivity in the U.S. until July 2026, although a non-automatically substitutable form of sitagliptin that differs from the form in the Company's sitagliptin products has been approved by the FDA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm)) |
| January 26, 2023 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-128 (Efficacy): submission_status AP, submission_status_date 20230126, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| March 28, 2023 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-132 (Efficacy): submission_status AP, submission_status_date 20230328, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| May 26, 2023 | [Zinplava (bezlotoxumab) label expansion decision](https://sec-api.dev/pdufa/bezlotoxumab) | MRK |  | completed, approved | "BLA761046 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20230526, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product ZINPLAVA (BEZLOTOXUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761046%22)) |
| June 5, 2023 | [Prevymis (letermovir) label expansion decision](https://sec-api.dev/pdufa/letermovir) | MRK |  | completed, approved | "NDA209940 SUPPL-11 (Efficacy): submission_status AP, submission_status_date 20230605, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product PREVYMIS (LETERMOVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209940%22)) |
| August 2, 2023 | [Prevymis (letermovir) label expansion decision](https://sec-api.dev/pdufa/letermovir) | MRK |  | completed, approved | "NDA209940 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20230802, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product PREVYMIS (LETERMOVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209940%22)) |
| August 14, 2023 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-134 (Efficacy): submission_status AP, submission_status_date 20230814, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| September 14, 2023 | [Temodar (temozolomide) label expansion decision](https://sec-api.dev/pdufa/temozolomide) | MRK |  | completed, approved | "NDA022277 SUPPL-18 (Efficacy): submission_status AP, submission_status_date 20230914, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product TEMODAR (TEMOZOLOMIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022277%22)) |
| October 12, 2023 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-138 (Efficacy): submission_status AP, submission_status_date 20231012, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| October 23, 2023 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-142 (Efficacy): submission_status AP, submission_status_date 20231023, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| November 7, 2023 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-148 (Efficacy): submission_status AP, submission_status_date 20231107, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| December 14, 2023 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-6 (Efficacy): submission_status AP, submission_status_date 20231214, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| December 15, 2023 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-151 (Efficacy): submission_status AP, submission_status_date 20231215, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| January 12, 2024 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-147 (Efficacy): submission_status AP, submission_status_date 20240112, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| January 25, 2024 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-124 (Efficacy): submission_status AP, submission_status_date 20240125, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| Mar 2024 | [Generic FDA approval](https://sec-api.dev/pdufa/generic) | MRK |  | completed, approved | "In March 2024, the Company filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey against Hikma, postponing FDA approval of the Hikma generic drug for 30 months or until expiration of the sugammadex patent (January 27, 2026) and any potentially applicable pediatric exclusivity or an adverse court decision, if any, whichever may occur earlier." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm)) |
| March 26, 2024 | [Winrevair (sotatercept-csrk) FDA approval](https://sec-api.dev/pdufa/sotatercept-csrk) | MRK | To treat pulmonary arterial hypertension | completed, approved | "Winrevair \| sotatercept-csrk \| 3/26/2024 \| To treat pulmonary arterial hypertensionDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| June 7, 2024 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-154 (Efficacy): submission_status AP, submission_status_date 20240607, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 26, 2024 | [Ohtuvayre (ensifentrine) FDA approval](https://sec-api.dev/pdufa/ensifentrine) | MRK | To treat chronic obstructive pulmonary disease | completed, approved | "Ohtuvayre \| ensifentrine \| 6/26/2024 \| To treat chronic obstructive pulmonary diseaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| August 7, 2024 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-157 (Efficacy): submission_status AP, submission_status_date 20240807, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| August 30, 2024 | [Prevymis (letermovir) FDA approval](https://sec-api.dev/pdufa/letermovir) | MRK |  | completed, approved | "NDA219104 ORIG-1 (Type 3 - New Dosage Form): submission_status AP, submission_status_date 20240830, review_priority PRIORITY; sponsor_name MSD; product PREVYMIS (LETERMOVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA219104%22)) |
| August 30, 2024 | [Prevymis (letermovir) label expansion decision](https://sec-api.dev/pdufa/letermovir) | MRK |  | completed, approved | "NDA209940 SUPPL-16 (Efficacy): submission_status AP, submission_status_date 20240830, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product PREVYMIS (LETERMOVIR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA209940%22)) |
| September 17, 2024 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-161 (Efficacy): submission_status AP, submission_status_date 20240917, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| September 26, 2024 | [KEYTRUDA® (pembrolizumab) FDA advisory committee meeting](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed | "The Committee will discuss the existing supplemental biologics license applications (sBLA) which were approved for patients with previously untreated HER2-negative unresectable or metastatic gastric or gastroesophageal adenocarcinoma: sBLA 125554/S-091 for OPDIVO (nivolumab) injection, submitted by Bristol Myers-Squibb Co. and sBLA 125514/S-143 for KEYTRUDA (pembrolizumab) injection, submitted by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc." ([FDA advisory committee calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/september-26-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-09262024)) |
| Nov 2024 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK |  | completed, positive | "In November 2024, Merck announced positive topline results from the Phase 3 ZENITH study, evaluating Winrevair in adults with PAH with WHO Group 1 FC III or IV at high risk of mortality." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm)) |
| December 11, 2024 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-162 (Efficacy): submission_status AP, submission_status_date 20241211, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| December 12, 2024 | [Bridion (sugammadex sodium) label expansion decision](https://sec-api.dev/pdufa/sugammadex) | MRK |  | completed, approved | "NDA022225 SUPPL-14 (Efficacy): submission_status AP, submission_status_date 20241212, review_priority PRIORITY; sponsor_name MSD SUB MERCK; product BRIDION (SUGAMMADEX SODIUM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA022225%22)) |
| Jan 2025 | [WINREVAIR (sotatercept) interim data readout](https://sec-api.dev/pdufa/sotatercept) | MRK |  | completed, positive | "In addition, in January 2025, Merck announced the Phase 3 HYPERION study evaluating Winrevair in newly diagnosed adults with PAH FC II or III at intermediate or high risk of disease progression was also stopped early based on the positive results from the interim analysis of the ZENITH trial and a review of the totality of data from the Winrevair clinical program to date." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000162828025007732/mrk-20241231.htm)) |
| January 28, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-172 (Efficacy): submission_status AP, submission_status_date 20250128, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| February 4, 2025 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "MSD outside the United States and Canada, today announced financial results for the fourth quarter of 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925008863/tm255059d1_ex99-1.htm)) |
| March 19, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-170 (Efficacy): submission_status AP, submission_status_date 20250319, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| April 15, 2025 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20250415, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| April 21, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-174 (Efficacy): submission_status AP, submission_status_date 20250421, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| April 24, 2025 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "RAHWAY, N.J., April 24, 2025 - Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925038301/tm2512885d1_ex99-1.htm)) |
| May 8, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Metastatic Esophageal Squamous Cell Carcinoma | withdrawn | "NCT04949256 (Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014).): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-05-08 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-20." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04949256)) |
| May 14, 2025 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20250514, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| May 21, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Cancer | completed | "NCT04895722 (Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895722)) |
| May 22, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-182 (Efficacy): submission_status AP, submission_status_date 20250522, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| May 26, 2025 | [MK-6482 PDUFA date](https://sec-api.dev/pdufa/mk-6482) | MRK |  | scheduled | "The FDA set a PDUFA date of May 26, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm)) |
| Jun 2025 | [LIPFENDRA (enlicitide) topline data readout](https://sec-api.dev/pdufa/enlicitide) | MRK | with hyperlipidemia | completed, positive | "In June 2025, Merck announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of MK-0616, enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm)) |
| June 3, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-173 (Efficacy): submission_status AP, submission_status_date 20250603, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 6, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Cancer, Muscle-invasive | completed | "NCT03924895 (Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-06 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03924895)) |
| June 9, 2025 | [Enflonsia (clesrovimab-cfor) FDA approval](https://sec-api.dev/pdufa/clesrovimab-cfor) | MRK |  | completed, approved | "Enflonsia \| clesrovimab-cfor \| 6/9/2025 \| To prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season Drug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| June 10, 2025 | [ENFLONSIA (clesrovimab) PDUFA date](https://sec-api.dev/pdufa/clesrovimab) | MRK |  | scheduled | "In December 2024, the FDA accepted the BLA for clesrovimab and set a PDUFA date of June 10, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm)) |
| June 13, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Non-Small Cell Lung Cancer | completed | "NCT03516981 (A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03516981)) |
| June 23, 2025 | [Cisplatin PDUFA date](https://sec-api.dev/pdufa/cisplatin) | MRK |  | scheduled | "The FDA set a PDUFA date of June 23, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828025021834/mrk-20250331.htm)) |
| June 23, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | completed | "NCT04924101 (Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04924101)) |
| June 27, 2025 | [Efinopegdutide primary completion](https://sec-api.dev/pdufa/efinopegdutide) | MRK |  | completed | "NCT06482112 (Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06482112)) |
| July 24, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-178 (Efficacy): submission_status AP, submission_status_date 20250724, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| July 25, 2025 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "USA Announces Second-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm)) |
| July 28, 2025 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hypercholesterolemia; Familial Hypercholesterolemia | completed | "NCT05952856 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952856)) |
| July 29, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Hepatocellular Carcinoma | completed | "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04740307)) |
| July 30, 2025 | [MK-6194 primary completion](https://sec-api.dev/pdufa/mk-6194) | MRK | Systemic Lupus Erythematosus | withdrawn | "NCT06161116 (Efficacy and Safety of MK-6194 in Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-30 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-10." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06161116)) |
| August 5, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed | "NCT05007106 (MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05007106)) |
| August 12, 2025 | [LYNPARZA® (olaparib) primary completion](https://sec-api.dev/pdufa/olaparib) | MRK | Advanced Solid Neoplasms | completed | "NCT03742895 (Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03742895)) |
| August 19, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Hepatocellular | withdrawn | "NCT04246177 (Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)): Overall Status TERMINATED; Phase PHASE3; Primary Completion 2025-08-19 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04246177)) |
| Sep 2025 | [MK-3475A FDA approval](https://sec-api.dev/pdufa/mk-3475a) | MRK |  | completed, approved | "September 2025, the U.S. Food and Drug Administration (FDA) approved KEYTRUDA QLEX injection for subcutaneous (SC) administration for use in adults across most solid tumor indications for KEYTRUDA, based on results from the Phase 3 MK-3475A-D77 trial." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_ex99-1.htm)) |
| Sep 2025 | [LIPFENDRA (enlicitide) topline data readout](https://sec-api.dev/pdufa/enlicitide) | MRK | with hypercholesterolemia | completed, positive | "In September 2025, Merck announced positive topline results from the Phase 3 CORALreef Lipids trial evaluating the safety and efficacy of enlicitide decanoate for the treatment of adults with hypercholesterolemia on a moderate or high intensity statin (or with documented statin intolerance)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm)) |
| September 3, 2025 | [Favezelimab/pembrolizumab primary completion](https://sec-api.dev/pdufa/favezelimab-pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT05508867 (A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05508867)) |
| September 19, 2025 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) FDA approval](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "Keytruda Qlex \| pembrolizumab and berahyaluronidase alfa-pmph \| 9/19/2025 \| To treat adult and pediatric (12 years and older) solid tumor indications approved for the intravenous formulation of pembrolizumab" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| September 23, 2025 | [KEYTRUDA® (pembrolizumab) PDUFA date](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | scheduled | "- 41 - approved solid tumor indications for Keytruda and set a Prescription Drug User Fee Act (PDUFA), or target action, date of September 23, 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015825000014/mrk-20250630.htm)) |
| October 13, 2025 | [Dor/isl primary completion](https://sec-api.dev/pdufa/dor-isl) | MRK | HIV-1 Infection | completed | "NCT05705349 (DOR/ISL in HIV-1 Antiretroviral Treatment-naïve Participants (MK-8591A-053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05705349)) |
| October 14, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | completed | "NCT03036488 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03036488)) |
| October 15, 2025 | [Bla761495 FDA approval](https://sec-api.dev/pdufa/bla761495) | MRK |  | completed, approved | "BLA761495 ORIG-1 (Type 9 - New indication submitted as distinct BLA, consolidated): submission_status AP, submission_status_date 20251015, review_priority PRIORITY; sponsor_name MERCK SHARP AND DOHME LLC; product n/a." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761495%22)) |
| October 16, 2025 | [Dor/isl primary completion](https://sec-api.dev/pdufa/dor-isl) | MRK | HIV Infection | completed | "NCT05766501 (A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-16 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05766501)) |
| October 24, 2025 | [Winrevair (sotatercept-csrk) label expansion decision](https://sec-api.dev/pdufa/sotatercept-csrk) | MRK |  | completed, approved | "BLA761363 SUPPL-7 (Efficacy): submission_status AP, submission_status_date 20251024, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WINREVAIR (SOTATERCEPT-CSRK)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761363%22)) |
| October 25, 2025 | [WINREVAIR (sotatercept) PDUFA date](https://sec-api.dev/pdufa/sotatercept) | MRK |  | scheduled | "FDA Granted Priority Review for WINREVAIR to Update Label Based on Results From ZENITH Trial; FDA Set PDUFA Date of Oct. 25, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925071380/tm2521736d1_ex99-1.htm)) |
| October 27, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Bladder Cancer | completed | "NCT04700124 (Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-10-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04700124)) |
| October 30, 2025 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "Inc., Rahway, N.J., USA Announces Third-Quarter 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_ex99-1.htm)) |
| October 31, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT04165083 (KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04165083)) |
| Nov 2025 | [IDVYNSO (doravirine-islatravir) topline data readout](https://sec-api.dev/pdufa/doravirine-islatravir) | MRK | HIV-1 infection in previously untreated adults, and in November 2025, the Company | completed, positive | "MK-8591A is also being evaluated for the treatment of HIV-1 infection in previously untreated adults, and in November 2025, the Company announced positive topline results from the pivotal Phase 3 MK-8591A-053 trial evaluating MK-8591A in this setting." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm)) |
| November 5, 2025 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Bladder Cancer | withdrawn | "NCT02625961 (Study of Pembrolizumab (MK-3475) and Pembrolizumab With Other Investigational Agents in Participants With High Risk Non-muscle Invasive Bladder Cancer (MK-3475-057/KEYNOTE-057)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-11-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-11-13." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02625961)) |
| November 20, 2025 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | completed | "NCT06664801 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-20 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06664801)) |
| November 21, 2025 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| November 21, 2025 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-188 (Efficacy): submission_status AP, submission_status_date 20251121, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| December 9, 2025 | [Recarbrio (cilastatin sodium; imipenem; relebactam) label expansion decision](https://sec-api.dev/pdufa/cilastatin-imipenem-relebactam) | MRK |  | completed, approved | "NDA212819 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20251209, review_priority STANDARD; sponsor_name MSD MERCK CO; product RECARBRIO (CILASTATIN SODIUM; IMIPENEM; RELEBACTAM)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA212819%22)) |
| December 22, 2025 | [V114 primary completion](https://sec-api.dev/pdufa/v114) | MRK | Acute Otitis Media (AOM) | completed | "NCT04193215 (V114 and Acute Otitis Media (V114-032/PNEU-ERA)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04193215)) |
| December 29, 2025 | [Efinopegdutide primary completion](https://sec-api.dev/pdufa/efinopegdutide) | MRK | Non-alcoholic Fatty Liver Disease; Fatty Liver, Nonalcoholic; NAFLD | completed | "NCT05877547 (A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05877547)) |
| January 14, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT02684292 (Study of Pembrolizumab (MK-3475) vs. Brentuximab Vedotin in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-204/KEYNOTE-204)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02684292)) |
| January 21, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed | "NCT04210115 (Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04210115)) |
| January 21, 2026 | [Verquvo (vericiguat) label expansion decision](https://sec-api.dev/pdufa/vericiguat) | MRK |  | completed, approved | "NDA214377 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20260121, review_priority STANDARD; sponsor_name MSD; product VERQUVO (VERICIGUAT)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA214377%22)) |
| January 26, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Bladder Cancer | completed | "NCT03924856 (Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-26 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03924856)) |
| January 27, 2026 | [Noxafil (posaconazole) label expansion decision](https://sec-api.dev/pdufa/posaconazole) | MRK |  | completed, approved | "NDA205596 SUPPL-21 (Efficacy): submission_status AP, submission_status_date 20260127, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product NOXAFIL (POSACONAZOLE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA205596%22)) |
| February 2, 2026 | [WELIREG® (belzutifan) primary completion](https://sec-api.dev/pdufa/belzutifan) | MRK | Carcinoma, Renal Cell | completed | "NCT04586231 (A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-02 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04586231)) |
| February 3, 2026 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "& Co., Inc., Rahway, N.J., USA Announces Fourth-Quarter and Full-Year 2025 Financial Results;" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm)) |
| February 3, 2026 | [Merck & Co., Inc. trial start](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "In 2025, the Company announced positive late-stage trial results from 18 Phase 3 trials and began enrolling patients in 21 new Phase 3 studies evaluating multiple indications and therapeutic areas, with approximately 80 Phase 3 studies currently underway." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm)) |
| February 4, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Renal Cell | completed | "NCT04736706 (A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04736706)) |
| February 4, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Renal Cell | completed | "NCT05899049 (A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-02-04 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05899049)) |
| February 10, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-2 (Efficacy): submission_status AP, submission_status_date 20260210, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| February 10, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-186 (Efficacy): submission_status AP, submission_status_date 20260210, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| February 20, 2026 | [MVASI® (bevacizumab) PDUFA date](https://sec-api.dev/pdufa/bevacizumab) | MRK |  | scheduled | "FDA Set PDUFA Date of Feb. 20, 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465925103974/tm2529620d1_ex99-1.htm)) |
| March 5, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Squamous Cell; Skin Neoplasms | withdrawn | "NCT06295809 (A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)): Overall Status TERMINATED; Phase PHASE2, PHASE3; Primary Completion 2026-03-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06295809)) |
| March 12, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Solid Tumor; Cutaneous Squamous Cell Carcinoma; Endometrial Cancer | completed | "NCT06036836 (Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06036836)) |
| March 12, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Lung Cancer; Non-Small Cell Lung Cancer | completed | "NCT06698042 (A Clinical Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) to Treat Newly-diagnosed Metastatic Non-small Cell Lung Cancer (MK-3475A-F84)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-03-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06698042)) |
| April 2, 2026 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Hidradenitis Suppurativa | completed | "NCT06956235 (Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-02 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06956235)) |
| April 7, 2026 | [KEYTRUDA® (pembrolizumab) PDUFA date](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | scheduled | "The FDA set a PDUFA date of April 7, 2026, marking the first concurrent review of both Keytruda and Keytruda Qlex for the same novel indication." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015825000059/mrk-20250930.htm)) |
| April 9, 2026 | [Frespaciguat primary completion](https://sec-api.dev/pdufa/frespaciguat) | MRK | Pulmonary Hypertension; Chronic Obstructive Pulmonary Disease | completed | "NCT05612035 (Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-04-09 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05612035)) |
| April 20, 2026 | [IDVYNSO (doravirine-islatravir) FDA approval](https://sec-api.dev/pdufa/doravirine-islatravir) | MRK |  | completed, approved | "Idvynso \| doravirine and islatravir \| 4/20/2026 \| To treat HIV-1 infection (as a complete regimen) in adults to replace the current antiretroviral regimen in those who are virologically-suppressed on a stable antiretroviral regimen with no history of virologic treatment failure and no known substitutions associated with resistance to doravirine" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| April 21, 2026 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | "NCT05144841 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-04-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05144841)) |
| April 24, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20260424, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| April 24, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms | completed | "NCT04895358 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-24 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895358)) |
| April 28, 2026 | [IDVYNSO (doravirine-islatravir) PDUFA date](https://sec-api.dev/pdufa/doravirine-islatravir) | MRK |  | completed, approved | "The FDA set a PDUFA, or target action, date of April 28, 2026 for the new drug application, which is based on findings of the Phase 3 MK-8591A-051 and MK-8591A-052 clinical trials." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/310158/000031015826000063/mrk-20251231.htm)) |
| April 30, 2026 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| June 1, 2026 | [Efinopegdutide topline data readout](https://sec-api.dev/pdufa/efinopegdutide) | MRK |  | completed | "NCT06482112 (Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-27 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06482112?tab=results)) |
| June 5, 2026 | [MK-1167 primary completion](https://sec-api.dev/pdufa/mk-1167) | MRK | Alzheimer Disease; Dementia | withdrawn | "NCT06721156 (A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-06-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06721156)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Non-Small Cell Lung Cancer | completed | "NCT03516981 (A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-13 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03516981?tab=results)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Solid Tumors | completed | "NCT04123366 (Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-06-08 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04123366)) |
| June 8, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Cancer | completed | "NCT04895722 (Evaluation of Co-formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008/KEYSTEP-008).): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-05-21 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-08." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04895722?tab=results)) |
| June 12, 2026 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-15 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| June 12, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-9 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| June 12, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-192 (Efficacy): submission_status AP, submission_status_date 20260612, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 15, 2026 | [Pembrolizumab/vibostolimab primary completion](https://sec-api.dev/pdufa/pembrolizumab-vibostolimab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT05298423 (Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-06-15 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05298423)) |
| June 19, 2026 | [WELIREG® (belzutifan) PDUFA date](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "Patients With Earlier-Stage RCC; Results From Phase 3 LITESPARK-022 Trial; FDA Set PDUFA Date of June 19, 2026 for WELIREG in combination with KEYTRUDA or KEYTRUDA QLEX" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| June 23, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Hepatocellular Carcinoma | completed | "NCT04740307 (Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-23." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04740307?tab=results)) |
| June 24, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| June 24, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-187 (Efficacy): submission_status AP, submission_status_date 20260624, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| June 30, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Cancer, Muscle-invasive | completed | "NCT03924895 (Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-06-06 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-06-30." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03924895?tab=results)) |
| 2H 2026 | [Trodelvy (sacituzumab govitecan) PDUFA date](https://sec-api.dev/pdufa/sacituzumab-govitecan) | MRK |  | scheduled | "The FDA set PDUFA dates in the second half of 2026 for these applications." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000162828026029802/mrk-20260331.htm)) |
| 2H 2026 | [ASCENT-04 PDUFA date](https://sec-api.dev/pdufa/ascent-04) | MRK |  | scheduled | "§ FDA set Prescription Drug User Fee Act (PDUFA) dates in the second half of 2026 for these applications." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926009495/tm264564d1_ex99-1.htm)) |
| July 1, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | completed | "NCT04924101 (Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-06-23 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-07-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04924101?tab=results)) |
| July 10, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260710, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| July 10, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-194 (Efficacy): submission_status AP, submission_status_date 20260710, review_priority PRIORITY; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| July 15, 2026 | [Lipfendra (enlicitide decanoate) FDA approval](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | To reduce low-density lipoprotein cholesterol | completed, approved | "Lipfendra \| enlicitide decanoate \| 7/15/2026 \| To reduce low-density lipoprotein cholesterol" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026)) |
| Aug to Nov 2026 | [Raludotatug deruxtecan (r-dxd) topline data readout](https://sec-api.dev/pdufa/raludotatug-deruxtecan-r-dxd) | MRK | Gastrointestinal Cancer | scheduled | "NCT06864169 (A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06864169)) |
| August 3, 2026 | [Efinopegdutide primary completion](https://sec-api.dev/pdufa/efinopegdutide) | MRK | Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD | completed | "NCT06465186 (A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465186)) |
| Aug to Nov 2026 | [Efinopegdutide topline data readout](https://sec-api.dev/pdufa/efinopegdutide) | MRK | Non-alcoholic Fatty Liver Disease; Nonalcoholic Steatohepatitis; NAFLD | scheduled | "NCT06465186 (A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06465186)) |
| August 3, 2026 | [LIPFENDRA (enlicitide) primary completion](https://sec-api.dev/pdufa/enlicitide) | MRK | Hyperlipidemia | completed | "NCT07216482 (A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216482)) |
| Aug to Nov 2026 | [LIPFENDRA (enlicitide) topline data readout](https://sec-api.dev/pdufa/enlicitide) | MRK | Hyperlipidemia | scheduled | "NCT07216482 (A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-037)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07216482)) |
| August 4, 2026 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "USA (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926090045/tm2621496d1_ex99-1.htm)) |
| August 6, 2026 | [Lipfendra (enlicitide decanoate) topline data readout](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hypercholesterolemia; Familial Hypercholesterolemia | completed | "NCT05952856 (A Study of Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-013) CORALreef Lipids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05952856?tab=results)) |
| August 12, 2026 | [Iv tulisokibart primary completion](https://sec-api.dev/pdufa/iv-tulisokibart) | MRK | Ulcerative Colitis | completed | "NCT06052059 (A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052059)) |
| Aug to Nov 2026 | [Iv tulisokibart topline data readout](https://sec-api.dev/pdufa/iv-tulisokibart) | MRK | Ulcerative Colitis | scheduled | "NCT06052059 (A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06052059)) |
| August 14, 2026 | [LYNPARZA® (olaparib) topline data readout](https://sec-api.dev/pdufa/olaparib) | MRK | Advanced Solid Neoplasms | completed | "NCT03742895 (Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2025-08-12 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-08-14." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03742895?tab=results)) |
| August 17, 2026 | [Cisplatin PDUFA date](https://sec-api.dev/pdufa/cisplatin) | MRK |  | scheduled | "§ FDA set PDUFA date of Aug. 17, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| August 2026 | [Raludotatug deruxtecan (r-dxd) primary completion](https://sec-api.dev/pdufa/raludotatug-deruxtecan-r-dxd) | MRK | Gastrointestinal Cancer | delayed | "NCT06864169 (A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06864169)) |
| September 1, 2026 | [Favezelimab/pembrolizumab topline data readout](https://sec-api.dev/pdufa/favezelimab-pembrolizumab) | MRK | Hodgkin Lymphoma | completed | "NCT05508867 (A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-09-03 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-01." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05508867?tab=results)) |
| September 7, 2026 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Arthritis, Rheumatoid | completed | "NCT07176390 (A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07176390)) |
| Sep to Dec 2026 | [Tulisokibart topline data readout](https://sec-api.dev/pdufa/tulisokibart) | MRK | Arthritis, Rheumatoid | scheduled | "NCT07176390 (A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-09-07 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07176390)) |
| September 21, 2026 | [MK-7962 PDUFA date](https://sec-api.dev/pdufa/mk-7962) | MRK |  | scheduled | "The FDA set a PDUFA date of September 21, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm)) |
| September 21, 2026 | [Winrevair (sotatercept-csrk) label expansion decision](https://sec-api.dev/pdufa/sotatercept-csrk) | MRK |  | completed, approved | "BLA761363 SUPPL-12 (Efficacy): submission_status AP, submission_status_date 20260921, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WINREVAIR (SOTATERCEPT-CSRK)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761363%22)) |
| September 24, 2026 | [WELIREG® (belzutifan) label expansion decision](https://sec-api.dev/pdufa/belzutifan) | MRK |  | completed, approved | "NDA215383 SUPPL-13 (Efficacy): submission_status AP, submission_status_date 20260924, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product WELIREG (BELZUTIFAN)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA215383%22)) |
| September 28, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed | "NCT05007106 (MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-08-05 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-09-28." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05007106?tab=results)) |
| Oct 2026 to Jan 2027 | [WELIREG® (belzutifan) topline data readout](https://sec-api.dev/pdufa/belzutifan) | MRK | Carcinoma, Renal Cell | scheduled | "NCT05239728 (A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05239728)) |
| October 4, 2026 | [MK-7902 PDUFA date](https://sec-api.dev/pdufa/mk-7902) | MRK |  | scheduled | "In the U.S., the FDA set a PDUFA date of October 4, 2026." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000212/mrk-20260630.htm)) |
| October 10, 2026 | [Merck & Co., Inc. PDUFA date](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | scheduled | "§ FDA set Prescription Drug User Fee Act (PDUFA) date of Oct. 10, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926052081/tm2612241d1_ex99-1.htm)) |
| October 14, 2026 | [Enflonsia (clesrovimab-cfor) label expansion decision](https://sec-api.dev/pdufa/clesrovimab-cfor) | MRK |  | completed, approved | "BLA761432 SUPPL-3 (Efficacy): submission_status AP, submission_status_date 20261014, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product ENFLONSIA (CLESROVIMAB-CFOR)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761432%22)) |
| October 16, 2026 | [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab) | MRK |  | completed, approved | "BLA761467 SUPPL-8 (Efficacy): submission_status AP, submission_status_date 20261016, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA QLEX (BERAHYALURONIDASE ALFA-PMPH; PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761467%22)) |
| October 16, 2026 | [KEYTRUDA® (pembrolizumab) label expansion decision](https://sec-api.dev/pdufa/pembrolizumab) | MRK |  | completed, approved | "BLA125514 SUPPL-191 (Efficacy): submission_status AP, submission_status_date 20261016, review_priority STANDARD; sponsor_name MERCK SHARP DOHME; product KEYTRUDA (PEMBROLIZUMAB)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125514%22)) |
| October 19, 2026 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Gastroesophageal Cancer | completed | "NCT06356311 (A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356311)) |
| Oct 2026 to Jan 2027 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Gastroesophageal Cancer | scheduled | "NCT06356311 (A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-19 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06356311)) |
| October 22, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | completed | "NCT03036488 (Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-10-14 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-22." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03036488?tab=results)) |
| October 2026 | [WELIREG® (belzutifan) primary completion](https://sec-api.dev/pdufa/belzutifan) | MRK | Carcinoma, Renal Cell | delayed | "NCT05239728 (A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05239728)) |
| October 29, 2026 | [Merck & Co., Inc. earnings report](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | completed | "USA Announces Third-Quarter 2026 Financial Results; Highlights Multiple Milestones Advancing Broad, Diverse Pipeline" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm)) |
| October 29, 2026 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | completed | "NCT04165083 (KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01B/KEYMAKER-U01B)): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-31 (ACTUAL); Lead Sponsor Merck Sharp & Dohme LLC; Results First Posted 2026-10-29." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04165083?tab=results)) |
| Nov 2026 to Feb 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Endometrial Neoplasms | scheduled | "NCT04634877 (Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04634877)) |
| November 2026 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Endometrial Neoplasms | scheduled | "NCT04634877 (Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04634877)) |
| Jan to Apr 2027 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04199689 (Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04199689)) |
| Jan to Apr 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Neoplasms | scheduled | "NCT04241185 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04241185)) |
| Jan to Apr 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05609968 (Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609968)) |
| January 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Carcinoma, Non-Small-Cell Lung | scheduled | "NCT05609968 (Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05609968)) |
| January 2027 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04199689 (Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04199689)) |
| January 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Urinary Bladder Neoplasms | scheduled | "NCT04241185 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-01-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04241185)) |
| Feb to May 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Hodgkin Lymphoma | scheduled | "NCT03407144 (Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03407144)) |
| Feb to May 2027 | [Tulisokibart topline data readout](https://sec-api.dev/pdufa/tulisokibart) | MRK | Psoriatic Arthritis | scheduled | "NCT07486960 (Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07486960)) |
| February 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Hodgkin Lymphoma | scheduled | "NCT03407144 (Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03407144)) |
| February 2027 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Psoriatic Arthritis | scheduled | "NCT07486960 (Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-02-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07486960)) |
| Mar to Jun 2027 | [Posaconazole iv 6 mg/kg topline data readout](https://sec-api.dev/pdufa/posaconazole-iv) | MRK | Invasive Fungal Infection | scheduled | "NCT04665037 (Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04665037)) |
| Mar to Jun 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Neoplasm Malignant | scheduled | "NCT04976634 (Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04976634)) |
| Mar to Jun 2027 | [Tulisokibart topline data readout](https://sec-api.dev/pdufa/tulisokibart) | MRK | Radiographic Axial Spondyloarthritis | scheduled | "NCT07133633 (A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07133633)) |
| March 22, 2027 | [ENFLONSIA (clesrovimab) PDUFA date](https://sec-api.dev/pdufa/clesrovimab) | MRK |  | scheduled | "In the U.S., the FDA set a PDUFA date of March 22, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm)) |
| March 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Neoplasm Malignant | scheduled | "NCT04976634 (Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04976634)) |
| March 2027 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Radiographic Axial Spondyloarthritis | scheduled | "NCT07133633 (A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographic Axial Spondyloarthritis (MK-7240-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-03-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07133633)) |
| March 2027 | [Posaconazole iv 6 mg/kg primary completion](https://sec-api.dev/pdufa/posaconazole-iv) | MRK | Invasive Fungal Infection | scheduled | "NCT04665037 (Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Years) With Invasive Fungal Infection (MK-5592-127)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04665037)) |
| April 22, 2027 | [IDVYNSO (doravirine-islatravir) PDUFA date](https://sec-api.dev/pdufa/doravirine-islatravir) | MRK |  | scheduled | "Idvynso is also under review in the U.S. to expand the approved indication in certain virologically suppressed adults with HIV-1 infection to include certain adults who have not previously received antiretroviral treatment; the FDA set a PDUFA date of April 22, 2027." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm)) |
| May to Aug 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Cancer; Anal Carcinoma; Anal Cancer | scheduled | "NCT02628067 (Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02628067)) |
| May to Aug 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | scheduled | "NCT04380636 (Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04380636)) |
| May to Aug 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Endometrial Neoplasms | scheduled | "NCT05173987 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05173987)) |
| May to Aug 2027 | [Nemtabrutinib topline data readout](https://sec-api.dev/pdufa/nemtabrutinib) | MRK | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624554)) |
| May to Aug 2027 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06074588 (Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074588)) |
| May to Aug 2027 | [WELIREG® (belzutifan) topline data readout](https://sec-api.dev/pdufa/belzutifan) | MRK | Metastatic Breast Cancer | scheduled | "NCT06428396 (Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06428396)) |
| May 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Advanced Cancer; Anal Carcinoma; Anal Cancer | scheduled | "NCT02628067 (Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT02628067)) |
| May 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Lung Neoplasms; Carcinoma, Non-Small-Cell Lung | scheduled | "NCT04380636 (Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04380636)) |
| May 2027 | [WELIREG® (belzutifan) primary completion](https://sec-api.dev/pdufa/belzutifan) | MRK | Metastatic Breast Cancer | scheduled | "NCT06428396 (Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-05-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06428396)) |
| May 2027 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06074588 (Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06074588)) |
| May 2027 | [Nemtabrutinib primary completion](https://sec-api.dev/pdufa/nemtabrutinib) | MRK | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05624554)) |
| May 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Endometrial Neoplasms | scheduled | "NCT05173987 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05173987)) |
| Jun to Sep 2027 | [Belsomra (suvorexant) topline data readout](https://sec-api.dev/pdufa/suvorexant) | MRK | Insomnia | scheduled | "NCT06655883 (A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06655883)) |
| Jun to Sep 2027 | [MK-6916 topline data readout](https://sec-api.dev/pdufa/mk-6916) | MRK | Pain Management | scheduled | "NCT07862595 (A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07862595)) |
| June 2027 | [MK-6916 primary completion](https://sec-api.dev/pdufa/mk-6916) | MRK | Pain Management | scheduled | "NCT07862595 (A Clinical Trial of MK-6916 in Participants With Pain After Bunion Removal Surgery (MK-6916-007)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-06-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07862595)) |
| June 15, 2027 | [Merck & Co., Inc. PDUFA date](https://sec-api.dev/companies/mrk/catalysts) | MRK |  | scheduled | "FDA set Prescription Drug User Fee Act (PDUFA) date of June 15, 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/310158/000110465926119825/tm2628203d1_ex99-1.htm)) |
| June 2027 | [Belsomra (suvorexant) primary completion](https://sec-api.dev/pdufa/suvorexant) | MRK | Insomnia | scheduled | "NCT06655883 (A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06655883)) |
| Jul to Oct 2027 | [Bomedemstat topline data readout](https://sec-api.dev/pdufa/bomedemstat) | MRK | Essential Thrombocythemia | scheduled | "NCT06079879 (A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079879)) |
| Jul to Oct 2027 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms | scheduled | "NCT06312176 (A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-11 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312176)) |
| Jul to Oct 2027 | [MK-8527 topline data readout](https://sec-api.dev/pdufa/mk-8527) | MRK | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | scheduled | "NCT07044297 (A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07044297)) |
| July 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms | scheduled | "NCT06312176 (A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-07-11 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06312176)) |
| July 2027 | [Bomedemstat primary completion](https://sec-api.dev/pdufa/bomedemstat) | MRK | Essential Thrombocythemia | scheduled | "NCT06079879 (A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-14 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06079879)) |
| July 2027 | [MK-8527 primary completion](https://sec-api.dev/pdufa/mk-8527) | MRK | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | scheduled | "NCT07044297 (A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-07-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07044297)) |
| Aug to Nov 2027 | [Isl topline data readout](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT06891066 (A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06891066)) |
| August 2027 | [Isl primary completion](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT06891066 (A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8591B-060)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-08-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06891066)) |
| Sep to Dec 2027 | [Zilovertamab vedotin topline data readout](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | DLBCL; Diffuse Large B-Cell Lymphoma | scheduled | "NCT05139017 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05139017)) |
| Sep to Dec 2027 | [Bomedemstat topline data readout](https://sec-api.dev/pdufa/bomedemstat) | MRK | Essential Thrombocythemia | scheduled | "NCT06456346 (Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456346)) |
| September 2027 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | DLBCL; Diffuse Large B-Cell Lymphoma | scheduled | "NCT05139017 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2027-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05139017)) |
| September 2027 | [Bomedemstat primary completion](https://sec-api.dev/pdufa/bomedemstat) | MRK | Essential Thrombocythemia | scheduled | "NCT06456346 (Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06456346)) |
| Oct 2027 to Jan 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | scheduled | "NCT04624204 (Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624204)) |
| Oct 2027 to Jan 2028 | [MK-8527 topline data readout](https://sec-api.dev/pdufa/mk-8527) | MRK | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | scheduled | "NCT07071623 (A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07071623)) |
| Oct 2027 to Jan 2028 | [MK-8690 topline data readout](https://sec-api.dev/pdufa/mk-8690) | MRK | Colitis Ulcerative; Ulcerative Colitis | scheduled | "NCT07463183 (A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07463183)) |
| Oct 2027 to Jan 2028 | [MK-7262 topline data readout](https://sec-api.dev/pdufa/mk-7262) | MRK | Lipoprotein(a) | scheduled | "NCT07614984 (A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614984)) |
| Oct 2027 to Jan 2028 | [MK-8690 topline data readout](https://sec-api.dev/pdufa/mk-8690) | MRK | Rheumatoid Arthritis | scheduled | "NCT07895524 (A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07895524)) |
| October 2027 | [MK-7262 primary completion](https://sec-api.dev/pdufa/mk-7262) | MRK | Lipoprotein(a) | scheduled | "NCT07614984 (A Clinical Trial of MK-7262 and Enlicitide in Participants With High Lipoprotein(a) (MK-7262-004)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07614984)) |
| October 2027 | [MK-8527 primary completion](https://sec-api.dev/pdufa/mk-8527) | MRK | Human Immunodeficiency Virus (HIV); HIV Pre-Exposure Prophylaxis | scheduled | "NCT07071623 (A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-10-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07071623)) |
| October 2027 | [MK-8690 primary completion](https://sec-api.dev/pdufa/mk-8690) | MRK | Rheumatoid Arthritis | scheduled | "NCT07895524 (A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07895524)) |
| October 2027 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Small Cell Lung Cancer | scheduled | "NCT04624204 (Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04624204)) |
| October 2027 | [MK-8690 primary completion](https://sec-api.dev/pdufa/mk-8690) | MRK | Colitis Ulcerative; Ulcerative Colitis | scheduled | "NCT07463183 (A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07463183)) |
| Nov 2027 to Feb 2028 | [Opevesostat topline data readout](https://sec-api.dev/pdufa/opevesostat) | MRK | Malignant Neoplasm | scheduled | "NCT06979596 (A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979596)) |
| Nov 2027 to Feb 2028 | [Lipfendra (enlicitide decanoate) topline data readout](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hyperlipidemia; Hypercholesterolemia | scheduled | "NCT07821944 (A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821944)) |
| November 2027 | [Opevesostat primary completion](https://sec-api.dev/pdufa/opevesostat) | MRK | Malignant Neoplasm | scheduled | "NCT06979596 (A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-11-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06979596)) |
| November 2027 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hyperlipidemia; Hypercholesterolemia | scheduled | "NCT07821944 (A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-11-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07821944)) |
| Dec 2027 to Mar 2028 | [Zilovertamab vedotin topline data readout](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Lymphoma, Large B-Cell, Diffuse | scheduled | "NCT06890884 (A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890884)) |
| Dec 2027 to Mar 2028 | [V503 topline data readout](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT07785843 (A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07785843)) |
| Dec 2027 to Mar 2028 | [Alimatravir topline data readout](https://sec-api.dev/pdufa/alimatravir) | MRK | HIV | scheduled | "NCT07850609 (A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07850609)) |
| December 2027 | [Alimatravir primary completion](https://sec-api.dev/pdufa/alimatravir) | MRK | HIV | scheduled | "NCT07850609 (A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07850609)) |
| December 2027 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Lymphoma, Large B-Cell, Diffuse | scheduled | "NCT06890884 (A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-12-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06890884)) |
| December 2027 | [V503 primary completion](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT07785843 (A Clinical Study of V503 in Chinese Females Who Have Previously Received a Bivalent Human Papillomavirus (HPV) Vaccine (V503-108)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07785843)) |
| Jan to Apr 2028 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Endometrial Cancer | scheduled | "NCT06132958 (Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132958)) |
| Jan to Apr 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06170788 (Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06170788)) |
| Jan to Apr 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Renal Cell Carcinoma | scheduled | "NCT06307431 (A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307431)) |
| Jan to Apr 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06345729)) |
| January 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Renal Cell Carcinoma | scheduled | "NCT06307431 (A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06307431)) |
| January 2028 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Endometrial Cancer | scheduled | "NCT06132958 (Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06132958)) |
| January 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06345729 (A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06345729)) |
| January 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06170788 (Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-01-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06170788)) |
| Mar to Jun 2028 | [V503 topline data readout](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT03998254 (Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03998254)) |
| Mar to Jun 2028 | [Pembrolizumab (+) berahyaluronidase alfa topline data readout](https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa) | MRK | Squamous Cell Carcinoma | scheduled | "NCT06041802 (A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06041802)) |
| March 2028 | [V503 primary completion](https://sec-api.dev/pdufa/v503) | MRK | Papillomavirus Infections | scheduled | "NCT03998254 (Efficacy, Immunogenicity and Safety of V503 in Chinese Women Aged 20-45 Years (V503-023)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03998254)) |
| March 2028 | [Pembrolizumab (+) berahyaluronidase alfa primary completion](https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa) | MRK | Squamous Cell Carcinoma | scheduled | "NCT06041802 (A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-03-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06041802)) |
| May to Aug 2028 | [Opevesostat topline data readout](https://sec-api.dev/pdufa/opevesostat) | MRK | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms | scheduled | "NCT06136650 (A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06136650)) |
| May 2028 | [Opevesostat primary completion](https://sec-api.dev/pdufa/opevesostat) | MRK | Metastatic Castration-resistant Prostate Cancer (mCRPC); Prostatic Neoplasms | scheduled | "NCT06136650 (A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-10 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06136650)) |
| Jun to Sep 2028 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Cervical Cancer | scheduled | "NCT06459180 (A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06459180)) |
| Jun to Sep 2028 | [Ifinatamab deruxtecan topline data readout](https://sec-api.dev/pdufa/ifinatamab-deruxtecan) | MRK | Prostate Cancer; Prostatic Neoplasms | scheduled | "NCT06925737 (A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06925737)) |
| Jun to Sep 2028 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT06925750 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06-16 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06925750)) |
| June 2028 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Cervical Cancer | scheduled | "NCT06459180 (A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-06-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06459180)) |
| June 2028 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT06925750 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-031/LIGHTRAY EXTENSION)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-06-16 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06925750)) |
| June 2028 | [Ifinatamab deruxtecan primary completion](https://sec-api.dev/pdufa/ifinatamab-deruxtecan) | MRK | Prostate Cancer; Prostatic Neoplasms | scheduled | "NCT06925737 (A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-06-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06925737)) |
| Jul to Oct 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | High-risk Non-muscle Invasive Bladder Cancer | scheduled | "NCT03711032 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03711032)) |
| Jul to Oct 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Malignant Melanoma | scheduled | "NCT06961006 (A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961006)) |
| July 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Malignant Melanoma | scheduled | "NCT06961006 (A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-07-22 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06961006)) |
| July 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | High-risk Non-muscle Invasive Bladder Cancer | scheduled | "NCT03711032 (Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-07-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03711032)) |
| Aug to Nov 2028 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06305754 (Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06305754)) |
| August 2028 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Non-small Cell Lung Cancer (NSCLC) | scheduled | "NCT06305754 (Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-08-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06305754)) |
| Sep to Dec 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Neoplasms | scheduled | "NCT05239741 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05239741)) |
| Sep to Dec 2028 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT05587712 (Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05587712)) |
| Sep to Dec 2028 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Malignant Neoplam; Advanced Solid Tumors | scheduled | "NCT07793942 (A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07793942)) |
| September 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Colorectal Neoplasms | scheduled | "NCT05239741 (Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-09-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05239741)) |
| September 2028 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT05587712 (Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-21 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05587712)) |
| September 2028 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Malignant Neoplam; Advanced Solid Tumors | scheduled | "NCT07793942 (A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-09-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07793942)) |
| Oct 2028 to Jan 2029 | [Iv tulisokibart topline data readout](https://sec-api.dev/pdufa/iv-tulisokibart) | MRK | Crohn's Disease | scheduled | "NCT06430801 (A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06430801)) |
| Oct 2028 to Jan 2029 | [Lipfendra (enlicitide decanoate) topline data readout](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hypercholesterolemia | scheduled | "NCT06492291 (Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06492291)) |
| Oct 2028 to Jan 2029 | [Tiespectus topline data readout](https://sec-api.dev/pdufa/tiespectus) | MRK | Diabetic Retinopathy; Macular Edema | scheduled | "NCT07705555 (A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07705555)) |
| October 2028 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Hypercholesterolemia | scheduled | "NCT06492291 (Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-10-13 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06492291)) |
| October 2028 | [Iv tulisokibart primary completion](https://sec-api.dev/pdufa/iv-tulisokibart) | MRK | Crohn's Disease | scheduled | "NCT06430801 (A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06430801)) |
| October 2028 | [Tiespectus primary completion](https://sec-api.dev/pdufa/tiespectus) | MRK | Diabetic Retinopathy; Macular Edema | scheduled | "NCT07705555 (A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-10-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07705555)) |
| Nov 2028 to Feb 2029 | [Pifeltro (doravirine) topline data readout](https://sec-api.dev/pdufa/doravirine) | MRK | Human Immunodeficiency Virus (HIV) Infection | scheduled | "NCT04375800 (Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04375800)) |
| Nov 2028 to Feb 2029 | [Opevesostat topline data readout](https://sec-api.dev/pdufa/opevesostat) | MRK | Prostate Cancer Metastatic | scheduled | "NCT06136624 (Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06136624)) |
| Nov 2028 to Feb 2029 | [Pembrolizumab (+) berahyaluronidase alfa topline data readout](https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa) | MRK |  | scheduled | "NCT06504394 (A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06504394)) |
| Nov 2028 to Feb 2029 | [Tiespectus topline data readout](https://sec-api.dev/pdufa/tiespectus) | MRK | Diabetic Retinopathy; Macular Edema | scheduled | "NCT07705607 (A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07705607)) |
| November 2028 | [Pembrolizumab (+) berahyaluronidase alfa primary completion](https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa) | MRK |  | scheduled | "NCT06504394 (A Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) Coformulated With Berahyaluronidase Alfa (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)(MK-3475A-F65)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2028-11-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06504394)) |
| November 2028 | [Pifeltro (doravirine) primary completion](https://sec-api.dev/pdufa/doravirine) | MRK | Human Immunodeficiency Virus (HIV) Infection | scheduled | "NCT04375800 (Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-11-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04375800)) |
| November 2028 | [Opevesostat primary completion](https://sec-api.dev/pdufa/opevesostat) | MRK | Prostate Cancer Metastatic | scheduled | "NCT06136624 (Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06136624)) |
| November 2028 | [Tiespectus primary completion](https://sec-api.dev/pdufa/tiespectus) | MRK | Diabetic Retinopathy; Macular Edema | scheduled | "NCT07705607 (A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-11-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07705607)) |
| Dec 2028 to Mar 2029 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT07218029 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218029)) |
| December 2028 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT07218029 (A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07218029)) |
| Jan to Apr 2029 | [Nemtabrutinib topline data readout](https://sec-api.dev/pdufa/nemtabrutinib) | MRK | Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma | scheduled | "NCT04728893 (Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04728893)) |
| Jan to Apr 2029 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer; NSCLC | scheduled | "NCT06422143 (Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06422143)) |
| January 2029 | [Nemtabrutinib primary completion](https://sec-api.dev/pdufa/nemtabrutinib) | MRK | Hematologic Malignancies; Waldenstroms Macroglobulinaemia; Non-Hodgkins Lymphoma | scheduled | "NCT04728893 (Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-01-04 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04728893)) |
| January 2029 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer; NSCLC | scheduled | "NCT06422143 (Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-12 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06422143)) |
| Feb to May 2029 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Genital Warts | scheduled | "NCT05314023 (Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05314023)) |
| February 2029 | [Isl primary completion](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT07266831 (A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-02-01 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266831)) |
| Feb to May 2029 | [Isl topline data readout](https://sec-api.dev/pdufa/isl) | MRK | Human Immunodeficiency Virus Type 1 (HIV-1) Infection | scheduled | "NCT07266831 (A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-02-01 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07266831)) |
| February 2029 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Genital Warts | scheduled | "NCT05314023 (Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-02-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05314023)) |
| Mar to Jun 2029 | [Calderasib topline data readout](https://sec-api.dev/pdufa/calderasib) | MRK | Colon Adenocarcinoma; Rectal Adenocarcinoma | scheduled | "NCT06997497 (A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06997497)) |
| March 2029 | [Calderasib primary completion](https://sec-api.dev/pdufa/calderasib) | MRK | Colon Adenocarcinoma; Rectal Adenocarcinoma | scheduled | "NCT06997497 (A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-03-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06997497)) |
| Apr to Jul 2029 | [Zilovertamab vedotin topline data readout](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Lymphoma, Large B-Cell, Diffuse (DLBCL) | scheduled | "NCT05406401 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-04-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05406401)) |
| Apr to Jul 2029 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06824467 (A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824467)) |
| Apr to Jul 2029 | [MK-2214 topline data readout](https://sec-api.dev/pdufa/mk-2214) | MRK | Early Alzheimer's Disease | scheduled | "NCT07033494 (A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07033494)) |
| Apr to Jul 2029 | [Ohtuvayre (ensifentrine) topline data readout](https://sec-api.dev/pdufa/ensifentrine) | MRK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07874815 (Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07874815)) |
| April 2029 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Lymphoma, Large B-Cell, Diffuse (DLBCL) | scheduled | "NCT05406401 (A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-04-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05406401)) |
| April 2029 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer | scheduled | "NCT06824467 (A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06824467)) |
| April 2029 | [Ohtuvayre (ensifentrine) primary completion](https://sec-api.dev/pdufa/ensifentrine) | MRK | Pulmonary Disease, Chronic Obstructive | scheduled | "NCT07874815 (Ensifentrine (MK-5884) Study for the Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in Adults With a History of Moderate or Severe Exacerbations While Receiving Standard of Care (SOC) (MK-5884-031/RPL554/ENHANCE-3)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-04-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07874815)) |
| April 2029 | [MK-2214 primary completion](https://sec-api.dev/pdufa/mk-2214) | MRK | Early Alzheimer's Disease | scheduled | "NCT07033494 (A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-04-30 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07033494)) |
| May to Aug 2029 | [MK-8591A topline data readout](https://sec-api.dev/pdufa/mk-8591a) | MRK | HIV-1 Infection | scheduled | "NCT04776252 (Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04776252)) |
| May to Aug 2029 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT05285826 (Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05285826)) |
| May to Aug 2029 | [Zilovertamab vedotin topline data readout](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma | scheduled | "NCT05458297 (A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-05-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05458297)) |
| May to Aug 2029 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT07646860 (A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07646860)) |
| May 2029 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Chronic Lymphocytic Leukemia; Mantle Cell Lymphoma; Follicular Lymphoma | scheduled | "NCT05458297 (A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2029-05-17 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05458297)) |
| May 2029 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Arterial Hypertension | scheduled | "NCT07646860 (A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-05-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07646860)) |
| May 2029 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT05285826 (Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05285826)) |
| May 2029 | [MK-8591A primary completion](https://sec-api.dev/pdufa/mk-8591a) | MRK | HIV-1 Infection | scheduled | "NCT04776252 (Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-05-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04776252)) |
| Jun to Sep 2029 | [Tulisokibart topline data readout](https://sec-api.dev/pdufa/tulisokibart) | MRK | Noninfectious Intermediate, Posterior, or Panuveitis | scheduled | "NCT07861074 (A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-06-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07861074)) |
| June 2029 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Noninfectious Intermediate, Posterior, or Panuveitis | scheduled | "NCT07861074 (A Clinical Trial Of Tulisokibart In Participants With Active, Non-Infectious Uveitis (MK-7240-019)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-06-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07861074)) |
| Jul to Oct 2029 | [Zilovertamab vedotin topline data readout](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Diffuse Large B-Cell Lymphoma | scheduled | "NCT06717347 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717347)) |
| Jul to Oct 2029 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Squamous Non-small Cell Lung Cancer | scheduled | "NCT07221474 (A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221474)) |
| Jul to Oct 2029 | [Sacituzumab tirumotecan topline data readout](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Bladder Cancer | scheduled | "NCT07419295 (A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07419295)) |
| July 2029 | [Zilovertamab vedotin primary completion](https://sec-api.dev/pdufa/zilovertamab-vedotin) | MRK | Diffuse Large B-Cell Lymphoma | scheduled | "NCT06717347 (A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06717347)) |
| July 2029 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Squamous Non-small Cell Lung Cancer | scheduled | "NCT07221474 (A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07-02 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07221474)) |
| July 2029 | [Sacituzumab tirumotecan primary completion](https://sec-api.dev/pdufa/sacituzumab-tirumotecan) | MRK | Bladder Cancer | scheduled | "NCT07419295 (A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-07-27 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07419295)) |
| Aug to Nov 2029 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT05450705 (V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-03 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05450705)) |
| Aug to Nov 2029 | [Verquvo (vericiguat) topline data readout](https://sec-api.dev/pdufa/vericiguat) | MRK | Heart Failure; Left Ventricular Systolic Dysfunction | scheduled | "NCT05714085 (Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05714085)) |
| August 2029 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT05450705 (V503 in Chinese Girls 9-14 Years Old Versus Chinese Women 20-26 Years Old (V503-071)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-08-03 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05450705)) |
| August 2029 | [Verquvo (vericiguat) primary completion](https://sec-api.dev/pdufa/vericiguat) | MRK | Heart Failure; Left Ventricular Systolic Dysfunction | scheduled | "NCT05714085 (Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)): Overall Status RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-08-20 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05714085)) |
| Sep to Dec 2029 | [Dor/isl topline data readout](https://sec-api.dev/pdufa/dor-isl) | MRK | HIV-1; HIV Infection | scheduled | "NCT07862569 (DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07862569)) |
| September 2029 | [Dor/isl primary completion](https://sec-api.dev/pdufa/dor-isl) | MRK | HIV-1; HIV Infection | scheduled | "NCT07862569 (DOR/ISL in Pediatric Participants With HIV-1, <18 Years of Age and ≥ 35 kg): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2029-09-24 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07862569)) |
| Oct 2029 to Jan 2030 | [9vhpv vaccine topline data readout](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04708041 (Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-23 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04708041)) |
| Oct 2029 to Jan 2030 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Melanoma | scheduled | "NCT05933577 (A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05933577)) |
| Oct 2029 to Jan 2030 | [Tulisokibart topline data readout](https://sec-api.dev/pdufa/tulisokibart) | MRK | Pulmonary Sarcoidosis | scheduled | "NCT07867938 (A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07867938)) |
| October 2029 | [Tulisokibart primary completion](https://sec-api.dev/pdufa/tulisokibart) | MRK | Pulmonary Sarcoidosis | scheduled | "NCT07867938 (A Clinical Trial of Tulisokibart (MK-7240) in Participants With Pulmonary Sarcoidosis (MK-7240-016)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-10-05 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07867938)) |
| October 2029 | [9vhpv vaccine primary completion](https://sec-api.dev/pdufa/9vhpv-vaccine) | MRK | Papillomavirus Infections | scheduled | "NCT04708041 (Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-23 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04708041)) |
| October 2029 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Melanoma | scheduled | "NCT05933577 (A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-10-26 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05933577)) |
| Nov 2029 to Feb 2030 | [Lipfendra (enlicitide decanoate) topline data readout](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Arteriosclerosis; Hypercholesterolaemia | scheduled | "NCT06008756 (Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008756)) |
| Nov 2029 to Feb 2030 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Malignant Neoplasm | scheduled | "NCT07252739 (KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-11-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07252739)) |
| November 2029 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Malignant Neoplasm | scheduled | "NCT07252739 (KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-11-15 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07252739)) |
| November 2029 | [Lipfendra (enlicitide decanoate) primary completion](https://sec-api.dev/pdufa/enlicitide-decanoate) | MRK | Arteriosclerosis; Hypercholesterolaemia | scheduled | "NCT06008756 (Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2029-11-29 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06008756)) |
| Dec 2029 to Mar 2030 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms; Breast Cancer | scheduled | "NCT06797635 (Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06797635)) |
| Dec 2029 to Mar 2030 | [Calderasib topline data readout](https://sec-api.dev/pdufa/calderasib) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT07190248 (A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190248)) |
| December 2029 | [Calderasib primary completion](https://sec-api.dev/pdufa/calderasib) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT07190248 (A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-12-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190248)) |
| December 2029 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Breast Neoplasms; Breast Cancer | scheduled | "NCT06797635 (Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-12-31 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06797635)) |
| Jan to Apr 2030 | [WINREVAIR (sotatercept) topline data readout](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Hypertension | scheduled | "NCT07839585 (A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07839585)) |
| January 2030 | [WINREVAIR (sotatercept) primary completion](https://sec-api.dev/pdufa/sotatercept) | MRK | Pulmonary Hypertension | scheduled | "NCT07839585 (A Clinical Study of Sotatercept (MK-7962) in People With Combined Postcapillary and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction (MK-7962-041)): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2030-01-08 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07839585)) |
| Feb to May 2030 | [Miransertib topline data readout](https://sec-api.dev/pdufa/miransertib) | MRK | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | scheduled | "NCT04980872 (A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-02-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04980872)) |
| February 2030 | [Miransertib primary completion](https://sec-api.dev/pdufa/miransertib) | MRK | PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS) | scheduled | "NCT04980872 (A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2030-02-07 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04980872)) |
| May to Aug 2030 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | scheduled | "NCT06841354 (A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841354)) |
| May 2030 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Triple Negative Breast Neoplasms | scheduled | "NCT06841354 (A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2030-05-18 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06841354)) |
| Jun to Sep 2030 | [KEYTRUDA® (pembrolizumab) topline data readout](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06077760 (A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06077760)) |
| June 2030 | [KEYTRUDA® (pembrolizumab) primary completion](https://sec-api.dev/pdufa/pembrolizumab) | MRK | Non-small Cell Lung Cancer | scheduled | "NCT06077760 (A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2030-06-25 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06077760)) |

## Drugs

- [9vhpv vaccine](https://sec-api.dev/pdufa/9vhpv-vaccine): Papillomavirus Infections, Genital Warts
- [Alimatravir](https://sec-api.dev/pdufa/alimatravir): HIV
- [ASCENT-04](https://sec-api.dev/pdufa/ascent-04): 
- [WELIREG® (belzutifan)](https://sec-api.dev/pdufa/belzutifan): Metastatic Breast Cancer, Carcinoma, Renal Cell
- [Keytruda Qlex (berahyaluronidase alfa-pmph; pembrolizumab)](https://sec-api.dev/pdufa/berahyaluronidase-alfa-pmph-pembrolizumab): 
- [Zinplava (bezlotoxumab)](https://sec-api.dev/pdufa/bezlotoxumab): 
- [Bla761495](https://sec-api.dev/pdufa/bla761495): 
- [Bomedemstat](https://sec-api.dev/pdufa/bomedemstat): Essential Thrombocythemia
- [Calderasib](https://sec-api.dev/pdufa/calderasib): Colon Adenocarcinoma, Non-small Cell Lung Cancer
- [Recarbrio (cilastatin sodium; imipenem; relebactam)](https://sec-api.dev/pdufa/cilastatin-imipenem-relebactam): 
- [ENFLONSIA (clesrovimab)](https://sec-api.dev/pdufa/clesrovimab): 
- [Enflonsia (clesrovimab-cfor)](https://sec-api.dev/pdufa/clesrovimab-cfor): 
- [Dor/isl](https://sec-api.dev/pdufa/dor-isl): HIV-1 Infection, HIV Infection, HIV-1
- [Pifeltro (doravirine)](https://sec-api.dev/pdufa/doravirine): Human Immunodeficiency Virus (HIV) Infection
- [IDVYNSO (doravirine-islatravir)](https://sec-api.dev/pdufa/doravirine-islatravir): hiv-1 infection in previously untreated adults, and in november 2025, the company
- [Delstrigo (doravirine; lamivudine; tenofovir disoproxil fumarate)](https://sec-api.dev/pdufa/doravirine-lamivudine-tenofovir-disoproxil): 
- [Efinopegdutide](https://sec-api.dev/pdufa/efinopegdutide): Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatotic Liver Disease
- [Zepatier (elbasvir; grazoprevir)](https://sec-api.dev/pdufa/elbasvir-grazoprevir): 
- [LIPFENDRA (enlicitide)](https://sec-api.dev/pdufa/enlicitide): with hyperlipidemia, with hypercholesterolemia, Hyperlipidemia
- [Lipfendra (enlicitide decanoate)](https://sec-api.dev/pdufa/enlicitide-decanoate): To reduce low-density lipoprotein cholesterol, Arteriosclerosis, Hyperlipidemia, Hypercholesterolemia
- [Ohtuvayre (ensifentrine)](https://sec-api.dev/pdufa/ensifentrine): To treat chronic obstructive pulmonary disease, Pulmonary Disease, Chronic Obstructive
- [Steglatro (ertugliflozin)](https://sec-api.dev/pdufa/ertugliflozin): 
- [Segluromet (ertugliflozin; metformin hydrochloride)](https://sec-api.dev/pdufa/ertugliflozin-metformin): 
- [Steglujan (ertugliflozin; sitagliptin phosphate)](https://sec-api.dev/pdufa/ertugliflozin-sitagliptin): 
- [Favezelimab/pembrolizumab](https://sec-api.dev/pdufa/favezelimab-pembrolizumab): Hodgkin Lymphoma
- [Frespaciguat](https://sec-api.dev/pdufa/frespaciguat): Pulmonary Hypertension
- [Ifinatamab deruxtecan](https://sec-api.dev/pdufa/ifinatamab-deruxtecan): Prostate Cancer
- [Isl](https://sec-api.dev/pdufa/isl): Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart): Ulcerative Colitis, Crohn's Disease
- [Prevymis (letermovir)](https://sec-api.dev/pdufa/letermovir): 
- [Janumet (metformin hydrochloride; sitagliptin phosphate)](https://sec-api.dev/pdufa/metformin-sitagliptin): 
- [Miransertib](https://sec-api.dev/pdufa/miransertib): PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
- [MK-1167](https://sec-api.dev/pdufa/mk-1167): Alzheimer Disease
- [MK-2214](https://sec-api.dev/pdufa/mk-2214): Early Alzheimer's Disease
- [MK-3475A](https://sec-api.dev/pdufa/mk-3475a): 
- [MK-6194](https://sec-api.dev/pdufa/mk-6194): Systemic Lupus Erythematosus
- [MK-6482](https://sec-api.dev/pdufa/mk-6482): 
- [MK-6916](https://sec-api.dev/pdufa/mk-6916): Pain Management
- [MK-7262](https://sec-api.dev/pdufa/mk-7262): Lipoprotein(a)
- [MK-7902](https://sec-api.dev/pdufa/mk-7902): 
- [MK-7962](https://sec-api.dev/pdufa/mk-7962): 
- [MK-8527](https://sec-api.dev/pdufa/mk-8527): Human Immunodeficiency Virus (HIV)
- [MK-8591A](https://sec-api.dev/pdufa/mk-8591a): HIV-1 Infection
- [MK-8690](https://sec-api.dev/pdufa/mk-8690): Colitis Ulcerative, Rheumatoid Arthritis
- [Nemtabrutinib](https://sec-api.dev/pdufa/nemtabrutinib): Hematologic Malignancies, Chronic Lymphocytic Leukemia
- [Opevesostat](https://sec-api.dev/pdufa/opevesostat): Malignant Neoplasm, Prostate Cancer Metastatic, Metastatic Castration-resistant Prostate Cancer (mCRPC)
- [KEYTRUDA® (pembrolizumab)](https://sec-api.dev/pdufa/pembrolizumab): advanced or metastatic merkel cell carcinoma, recurrent solid tumors, muscle-invasive bladder cancer, Urinary Bladder Neoplasms, Urinary Bladder Cancer, Muscle-invasive, Breast Neoplasms, Advanced Cancer, High-risk Non-muscle Invasive Bladder Cancer
- [Pembrolizumab (+) berahyaluronidase alfa](https://sec-api.dev/pdufa/pembrolizumab-berahyaluronidase-alfa): Squamous Cell Carcinoma, Classical Hodgkin Lymphoma Recurrent
- [Pembrolizumab/vibostolimab](https://sec-api.dev/pdufa/pembrolizumab-vibostolimab): Carcinoma, Non-Small-Cell Lung
- [Noxafil (posaconazole)](https://sec-api.dev/pdufa/posaconazole): 
- [Posaconazole iv 6 mg/kg](https://sec-api.dev/pdufa/posaconazole-iv): Invasive Fungal Infection
- [Isentress (raltegravir potassium)](https://sec-api.dev/pdufa/raltegravir): 
- [Raludotatug deruxtecan (r-dxd)](https://sec-api.dev/pdufa/raludotatug-deruxtecan-r-dxd): Gastrointestinal Cancer
- [Trodelvy (sacituzumab govitecan)](https://sec-api.dev/pdufa/sacituzumab-govitecan): 
- [Sacituzumab tirumotecan](https://sec-api.dev/pdufa/sacituzumab-tirumotecan): non-small cell lung cancer, Bladder Cancer, Cervical Cancer, Non-small Cell Lung Cancer (NSCLC), Gastroesophageal Cancer, Ovarian Cancer, Endometrial Cancer
- [Januvia (sitagliptin)](https://sec-api.dev/pdufa/sitagliptin): 
- [WINREVAIR (sotatercept)](https://sec-api.dev/pdufa/sotatercept): Pulmonary Arterial Hypertension, Pulmonary Hypertension
- [Winrevair (sotatercept-csrk)](https://sec-api.dev/pdufa/sotatercept-csrk): To treat pulmonary arterial hypertension
- [Bridion (sugammadex sodium)](https://sec-api.dev/pdufa/sugammadex): 
- [Belsomra (suvorexant)](https://sec-api.dev/pdufa/suvorexant): Insomnia
- [Temodar (temozolomide)](https://sec-api.dev/pdufa/temozolomide): Glioblastoma
- [Tiespectus](https://sec-api.dev/pdufa/tiespectus): Diabetic Retinopathy
- [Tulisokibart](https://sec-api.dev/pdufa/tulisokibart): Hidradenitis Suppurativa, Pulmonary Sarcoidosis, Psoriatic Arthritis, Radiographic Axial Spondyloarthritis, Arthritis, Rheumatoid, Noninfectious Intermediate, Posterior, or Panuveitis
- [V114](https://sec-api.dev/pdufa/v114): Acute Otitis Media (AOM)
- [V503](https://sec-api.dev/pdufa/v503): Papillomavirus Infections
- [Verquvo (vericiguat)](https://sec-api.dev/pdufa/vericiguat): Heart Failure
- [Zilovertamab vedotin](https://sec-api.dev/pdufa/zilovertamab-vedotin): Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse (DLBCL), Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Lymphoma, Large B-Cell, Diffuse, DLBCL, Diffuse Large B-Cell Lymphoma

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mrk/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MRK catalysts: Merck & Co., Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mrk/catalysts

```bibtex
@misc{secapidev_companies_mrk_catalysts_20261116,
  title        = {MRK catalysts: Merck & Co., Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mrk/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mrk_catalysts_20261116","title":"MRK catalysts: Merck & Co., Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mrk/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
